AVITA Medical Welcomes Support for RECELL® in Burns in Australia

Core Insights - Australia's Medical Services Advisory Committee (MSAC) has recommended amendments to the Medicare Benefits Schedule to include the use of autologous skin cell suspension (ASCS) prepared with RECELL for treating severe acute burn wounds in both adults and children [1][2] Company Overview - AVITA Medical, Inc. is a leading therapeutic acute wound care company focused on delivering transformative solutions that optimize wound healing and accelerate patient recovery [4] - The RECELL System is at the forefront of AVITA Medical's platform, approved by the U.S. Food and Drug Administration for treating thermal burn and trauma wounds [4] Clinical Impact - MSAC's endorsement highlights RECELL's clinical effectiveness, demonstrating that it is as safe and effective as traditional autologous skin grafting while offering superior outcomes in donor site sparing and reducing the need for additional grafting procedures [2][3] - RECELL can shorten hospital stays, alleviate patient pain, and minimize scarring, thus improving overall patient outcomes [2][3] Treatment Applications - The MSAC recommendation supports the use of RECELL for adult patients with burns covering 20% or more of total body surface area (TBSA) and pediatric patients with burns covering 10% or more TBSA, including whole-of-face burn wound closure [7]